Know Cancer

forgot password

Chemoembolisation With Irinotecan Loaded DC Bead (DEBIRI) in Combination With Cetuximab and 5FU/LV in the First Line Treatment of Patients With KRAS Wildtype Metastatic Colorectal Cancer (mCRC)

18 Years
Not Enrolling
Liver Metastases, Colorectal Cancer

Thank you

Trial Information

Chemoembolisation With Irinotecan Loaded DC Bead (DEBIRI) in Combination With Cetuximab and 5FU/LV in the First Line Treatment of Patients With KRAS Wildtype Metastatic Colorectal Cancer (mCRC)

20 patients will be included. The duration of the trial will be approximately 24 months.

Every 8 weeks there will be a tumour lesion assessment.

Inclusion Criteria:

1. Confirmed diagnosis of stage IV KRAS wild-type colorectal adenocarcinoma, with
metastases predominantly in the liver (≥80% of tumor burden) that are deemed

2. Primary tumour has been treated with complete surgical resection without evidence of
residual tumour

3. Patients must have at least 1 measurable lesion (RECIST criteria)

4. Performance status ECOG 0-1

5. Aged ≥18 years

6. Life expectancy > 3 months

7. No prior chemotherapy for metastatic disease

8. Hematologic function: WBC ≥ 3.0 x 10*9/L, platelets ≥ 100 x10*9/L

9. Adequate organ function as measured by:

- Serum creatinine £ 1.5 x upper limit of normal (ULN)

- Serum transaminases (AST & ALT) £ 5 x ULN

- Bilirubin> 1.5 times the upper limit of the normal range

10. Women of child bearing potential and fertile men are required to use effective
contraception (negative βHCG for women of child-bearing age)

11. Signed, written informed consent

12. Patients with patent main portal vein

13. Maximum liver involvement ≤60%

Exclusion Criteria:

1. Presence of CNS metastases

2. Contraindications to FU/LV, Irinotecan or Cetuximab

3. Active bacterial, viral or fungal infection within 72 hours of study entry

4. Women who are pregnant or breast feeding

5. Allergy to contrast media or history of severe hypersensitivity to study drugs.

6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years
except adequately treated basal or squamous cell skin cancer or carcinoma in situ of
the cervix

7. Any contraindication for hepatic embolization procedures:

- porto-systemic shunt

- hepatofugal blood flow

- severe atheromatosis

8. Contraindication to hepatic artery catheterization, such as a patient with severe
peripheral vascular disease precluding catheterization

9. Other significant medical or surgical condition, or any medication or treatment
regimens, that would place the patient at undue risk, that would preclude the safe
use of chemoembolization or would interfere with study participation

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Feasibility of chemoembolization with DC Bead loaded with Irinotecan

Outcome Description:

Feasibility of the study by measuring the number of enrolled patients who can finish the first cycle of treatment

Outcome Time Frame:

after one cycle = after 8 weeks

Safety Issue:


Principal Investigator

Eric Van Cutsem, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Universitaire Ziekenhuizen Leuven


Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:




Start Date:

September 2012

Completion Date:

October 2014

Related Keywords:

  • Liver Metastases
  • Colorectal Cancer
  • chemoembolization
  • DC Bead™
  • Irinotecan
  • Cetuximab
  • 5FU/LV
  • KRAS
  • metastatic colorectal cancer
  • Colorectal Neoplasms
  • Neoplasm Metastasis
  • Liver Neoplasms